The carcinogen 2-acetylaminofluorene inhibits activation and nuclear accumulation of cyclin-dependent kinase 2 in growth-induced rat liver

Molecular Carcinogenesis

Volumn 27, Issue 3, 2000, Pages 190-199

  Lindeman, Birgitte ^a   Skarpen, Ellen ^b   Oksvold, Morten P ^b   Huitfeldt, Henrik S ^b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b NONE

Author keywords

Cyclin E; Growth arrest; p21(waf1 cip1); p53; Partial hepatectomy

Indexed keywords

CARCINOGEN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN E; N (2 FLUORENYL)ACETAMIDE; PROTEIN P21; PROTEIN P53;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL CYCLE; CELL FRACTIONATION; CONTROLLED STUDY; DNA DAMAGE; ENZYME ASSAY; GROWTH INHIBITION; LIVER CELL; LIVER REGENERATION; LIVER RESECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

2-ACETYLAMINOFLUORENE; ANIMALS; CARCINOGENS; CDC2-CDC28 KINASES; CELL DIVISION; CELL NUCLEUS; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME ACTIVATION; LIVER; LIVER REGENERATION; MALE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, INBRED F344; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 0034057430     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(200003)27:3<190::AID-MC6>3.0.CO;2-N     Document Type: Article

References (69)

1. 1-S phase protein kinase. Science 1992;257: 1958-1961.
2. 1 phase of the human cell cycle. Science 1992;257:1689-1694.
3. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY. D type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 1994;14:2066-2076.
4. Morgan DO. Principles of CDK regulation. Nature 1995; 374:131-134.
5. Sherr CJ. G1 phase progression: Cycling on cue. Cell 1994; 79:551-555.
6. Pines J. Cyclins and cyclin-dependent kinases: Theme and variations. Adv Cancer Res 1995;66:181-212.
7. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 1992;11:3995-4005.
8. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
9. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 1996; 8:805-814.
10. Harrington EA, Bruce JL, Harlow E, Dyson N. pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc Natl Acad Sci USA 1998;95:11945-11950.
11. Ezhevsky SA, Nagahara H, Vocero-Akbani AM, Gius DR, Wei MC, Dowdy SF. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci USA 1997;94: 10699-10704.
12. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998;18:753-761.
13. 1-to-S phase transition. Mol Cell Biol 1995;15: 2612-2624.
14. Lukas J, Herzinger T, Hansen K, et al. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev 1997;11:1479-1492.
15. Dulic V, Kaufmann WK, Wilson SJ, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76:1013-1023.
16. 1 arrest and apoptosis. Cancer Res 1994;54:1169-1174.
17. 1 cyclin-cdk protein kinase activity, is related to p21. Cell 1994; 78:67-74.
18. Spitkovsky D, Schulze A, Boye B, Jansen-Dürr P. Downregulation of cyclin A gene expression upon genotoxic stress correlates with reduced binding of free E2F to the promoter. Cell Growth Differ 1997;8:699-710.
19. Yuan ZM, Huang Y, Kraeft SK, Chen LB, Kharbanda S, Kufe D. Interaction of cydin-dependent kinase 2 and the Lyn tyrosine kinase in cells treated with 1-beta-D-arabinofuranosylcytosine. Oncogene 1996;13:939-946.
20. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
21. Lu X, Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 1993;75: 765-778.
22. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
23. Gartel AL, Serfas MS, Tyner AL. p21 - negative regulator of the cell cycle. Proc Soc Exp Biol Med 1996;213: 138-149.
24. Steer CJ. Liver regeneration. FASEB J 1995;9:1396-1400.
25. Heflich RH, Neft RE. Genetic toxicity of 2-acetylaminofluorene, 2-aminofluorene and some of their metabolites and model metabolites. Mutation Res 1994;318:73-174.
26. Solt D, Farber E. New principle for the analysis of chemical carcinogenesis. Nature 1976;263:701-703.
27. Tatematsu M, Aoki T, Kagawa M, Mera Y, Ito N. Reciprocal relationship between development of glutathione S-transferase positive liver foci and proliferation of surrounding hepatocytes in rats. Carcinogenesis 1988;9:221-225.
28. Farber E. Clonal adaptation during carcinogenesis. Biochem Pharmacol 1990;39:1837-1846.
29. Rissler P, Torndal UB, Eriksson LC. Induced drug resistance inhibits selection of initiated cells and cancer development. Carcinogenesis 1997;18:649-655.
30. van Gijssel HE, Maassen CBM, Mulder GJ, Meerman JHN. p53 protein expression by hepatocarcinogens in the rat liver and its potential role in mitoinhibition of normal hepatocytes as a mechanism of hepatic tumour promotion. Carcinogenesis 1997;18:1027-1033.
31. Ohlson LCE, Koroxenidou L, Hallstrom IP. Inhibition of in vivo rat liver regeneration by 2-acetylaminofluorene affects the regulation of cell cycle-related proteins. Hepatology 1998;27:691-696.
32. 1 cell-cycle protein expression and induction of p53 but not p21/waf1 by the DNA-modifying carcinogen 2-acetylaminofluorene in growth-stimulated hepatocytes in vitro. Mol Carcinog 1999;24:36-46.
33. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
34. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4354.
35. Mittnacht S, Weinberg RA. G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell 1991;65:381-393.
36. Tiwawech D, Hasegawa R, Kurata Y, et al. Dose-dependent effects of 2-acetylaminofluorene on hepatic foci development and cell proliferation in rats. Carcinogenesis 1991;12: 985-990.
37. Kitagawa M, Higashi H, Jung HK, et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 1996;15:7060-7069.
38. 1 phases of the cell cycle. Cell Growth Differ 1996;7:1283-1290.
39. Dietrich C, Wallenfang K, Oesch F, Wieser R. Translocation of cdk2 to the nucleus during G1-phase in PDGF-stimulated human fibroblasts. Exp Cell Res 1997;232:72-78.
40. Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993;366:707-710.
41. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816.
42. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-704.
43. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
44. Lee MH, Reynisdottir I, Massagué J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-649.
45. Loyer P, Glaise D, Cariou S, Baffet G, Meijer L, Guguen-Guillouzo C. Expression and activation of cdks (1 and 2) and cyclins in the cell cycle progression during liver regeneration. J Biol Chem 1994;269:2491-2500.
46. Albrecht JH, Poon RYC, Ahonen CL, Rieland BM, Deng C, Crary GS. Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver. Oncogene 1998;16:2141-2150.
47. Horton LE, Templeton DJ. The cyclin box and C-terminus of cyclins A and E specify CDK activation and substrate specificity. Oncogene 1997;14:491-498.
48. Kelly BL, Wolfe KG, Roberts JM. Identification of a substrate-targeting domain in cyclin E necessary for phosphorylation of the retinoblastoma protein. Proc Natl Acad Sci USA 1998;95:2535-2540.
49. Schulman BA, Lindstrom DL, Harlow E. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc Natl Acad Sci USA 1998;95: 10453-10458.
50. Desai D, Wessling HC, Fisher RP, Morgan DO. Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. Mol Cell Biol 1995;15:345-350.
51. Jaumont M, Estanyol JM, Serratosa J, Agell N, Bachs O. Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin-cdk complexes. Hepatology 1999;29:385-395.
52. Maridor G, Gallant P, Golsteyn R, Nigg EA. Nuclear localization of vertebrate cyclin A correlates with its ability to form complexes with cdk catalytic subunits J Cell Sci 1993;106:535-544.
53. Pines J, Hunter T. The differential localization of human cyclins A and B is due to a cytoplasmic retention signal in cyclin B. EMBO J 1994;13:3772-3781.
54. Reed SI. Cyclin E: In mid-cycle. Biochim Biophys Acta 1996;1287:151-153.
55. Moore JD, Yang J, Truant R, Kornbluth S. Nuclear import of cdk/cyclin complexes: identification of distinct mechanisms for import of cdk2/cyclin E and cdc2/cyclin B1. J Cell Biol 1999;144:213-224.
56. Jeffrey PD, Russo AA, Polyak K, et al. Mechanism of CDK activation revealed by the structure of a cyclinA-cdk2 complex. Nature 1995;376:313-320.
57. Russo AA, Jeffrey PD, Pavletich NP. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol 1996;3:696-700.
58. Larochelle S, Pandur J, Fisher RP, Salz HK, Suter B. Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity. Genes Dev 1998;12:370-381.
59. Tassan JP, Schultz SJ, Bartek J, Nigg EA. Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J Cell Biol 1994;127:467-478.
60. Matsuoka M, Kato JY, Fisher RP, Morgan DO, Sherr CJ. Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol Cell Biol 1994;14: 7265-7275.
61. MO15. J Cell Sci 1994;107:2789-2799.
62. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor supression. Cell 1993;75: 817-825.
63. Fotedar R, Fitzgerald P, Rousselle T, et al. p21 contains independent binding sites for cyclin and cdk2: Both sites are required to inhibit cdk2 kinase activity. Oncogene 1996;12: 2155-2164.
64. Flores-Rozas H, Kelman Z, Dean FB, et al. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci USA 1994;91:8655-8659.
65. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994;371:534-537.
66. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-578.
67. Dimri GP, Nakanishi M, Desprez P, Smith JR, Campisi J. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol 1996; 16:2987-2997.
68. Kato JY, Matsuoka M, Polyak K, Massagué J, Sherr CJ. Cyclic AMP induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 1994;79:487-496.
69. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996;382:325-331.